Altered Levels of Malondialdehyde and Vitamin E in Major Depressive Disorder and Generalized Anxiety Disorder

被引:16
|
作者
Bal, Nilgun [1 ]
Acar, Senel Tot [2 ]
Yazici, Aylin [2 ]
Yazici, Kemal [2 ]
Tamer, Lulufer [3 ]
机构
[1] Erdemi State Hosp, Dept Psychiat, Mersin, Turkey
[2] Erdemi State Hosp, Med Sch, Dept Psychiat, Mersin, Turkey
[3] Mersin Univ, Med Sch, Dept Biochem, Mersin, Turkey
来源
DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES | 2012年 / 25卷 / 03期
关键词
Major depressive disorder; generalized anxiety disorder; oxidative stress; antioxidant defence systems;
D O I
10.5350/DAJPN2012250302
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction: Reactive oxygen species (ROS) may play a role in some neuropsychiatric disorders. There is some evidence that the activation of immune-inflammatory processes, an increase in monoamines catabolism and abnormalities in lipid compounds may cause overproduction of ROS and lipid peroxidation. These phenomena may be related to pathophysiology of major depressive disorder and generalized anxiety disorder. Malondialdehyde (MDA) is the end product of lipid peroxidation. Vitamin E is thought to play an important role as an antioxidant against lipid peroxidation. This study aims to investigate the role of oxygen radicals in the etiology of major depressive disorder and generalized anxiety disorder. Method: Plasma MDA and vitamin E levels of patients with major depressive disorder (n=42) and generalized anxiety disorder (n=37) were compared with healthy controls (n=38). To assess depressive symptoms and anxiety symptoms, Hamilton Depression Scale and Hamilton Anxiety Scale were applied. Results: Patients with major depressive disorder and generalized anxiety disorder had higher MDA and lower vitamin E levels than those of healthy controls. Differences between the patient and the control groups according to these two parameters were found statistically significant. Conclusion: Our results support the hypothesis that oxidative stress may affect depressive and anxiety symptoms. As a result, free radical damage and deficiency of antioxidant defence systems may have an important role in major depressive disorder and generalized anxiety disorder.
引用
收藏
页码:206 / 211
页数:6
相关论文
共 50 条
  • [31] Comorbidity of Migraine, Major Depressive Disorder, and Generalized Anxiety Disorder in Adolescents and Young Adults
    Lilian N. Dindo
    Ana Recober
    Rita Haddad
    Chadi A. Calarge
    International Journal of Behavioral Medicine, 2017, 24 : 528 - 534
  • [32] Serum lipid concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder
    Sevincok, L
    Buyukozturk, A
    Dereboy, F
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2001, 46 (01): : 68 - 71
  • [33] NORADRENERGIC FUNCTION IN GENERALIZED ANXIETY DISORDER, MAJOR DEPRESSIVE DISORDER, AND HEALTHY-SUBJECTS
    SEVY, S
    PAPADIMITRIOU, GN
    SURMONT, DW
    GOLDMAN, S
    MENDLEWICZ, J
    BIOLOGICAL PSYCHIATRY, 1989, 25 (02) : 141 - 152
  • [34] Altered levels of salivary cytokines in patients with major depressive disorder
    Yui, Sumie
    Sasayama, Daimei
    Yamaguchi, Masaki
    Washizuka, Shinsuke
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2022, 221
  • [35] Levels of Cyberchondria in Anxiety Disorder and Depressive Disorder
    Ozdemir, Mehmet
    Erdogan, Ali
    Eryilmaz, Mustafa Mehmet
    ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES, 2022, 59 (01): : 36 - 41
  • [36] The structure of distress following trauma: Posttraumatic stress disorder, major depressive disorder, and generalized anxiety disorder
    Grant, DeMond M.
    Beck, J. Gayle
    Marques, Luana
    Palyo, Sarah A.
    Clapp, Joshua D.
    JOURNAL OF ABNORMAL PSYCHOLOGY, 2008, 117 (03) : 662 - 672
  • [37] Evaluation of Coronavirus Anxiety Levels and Coping Strategies of Major Depressive Disorder, Generalized Anxiety Disorder, and Panic Disorder Patients During the Covid-19 Pandemic
    Erden, Selime Celik
    Uygur, Abdullah Burak
    Karakus, Kadir
    MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL, 2023, 57 (01): : 33 - 45
  • [38] Venlafaxine in depressive disorder comorbid with generalized anxiety disorder
    Kulenovic, A. Dzubur
    Kucukalic, A.
    Bravo-Mehmedbasic, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S466 - S467
  • [39] PANIC DISORDER, GENERALIZED ANXIETY DISORDER AND DEPRESSIVE COMORBIDITY
    Aloulou, J.
    Halouani, N.
    Charfeddine, F.
    Abida, I.
    Amami, O.
    EUROPEAN PSYCHIATRY, 2012, 27
  • [40] Generalized anxiety disorder comorbidities: Panic and depressive disorder
    Turki, M.
    Ben Thabet, J.
    Charfi, N.
    Mezghanni, M.
    Bouali, M. Maalej
    Zouari, N.
    Zouari, L.
    Maalej, M.
    EUROPEAN PSYCHIATRY, 2017, 41 : S486 - S486